Format

Send to

Choose Destination
Int J Med Microbiol. 2014 Jan;304(1):3-13. doi: 10.1016/j.ijmm.2013.09.004. Epub 2013 Sep 4.

Future potential for anti-infectives from bacteria - how to exploit biodiversity and genomic potential.

Author information

1
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), P.O. Box 151150, 66041 Saarbrücken, Germany; Helmholtz Centre for Infectious Research (HZI), Inhoffenstrasse 7, 38124 Braunschweig, Germany.
2
Helmholtz Centre for Infectious Research (HZI), Inhoffenstrasse 7, 38124 Braunschweig, Germany. Electronic address: joachim.wink@helmholtz-hzi.de.

Abstract

The early stages of antibiotic development include the identification of novel hit compounds. Since actinomycetes and myxobacteria are still the most important natural sources of active metabolites, we provide an overview on these producers and discuss three of the most promising approaches toward finding novel anti-infectives from microorganisms. These are defined as the use of biodiversity to find novel producers, the variation of culture conditions and induction of silent genes, and the exploitation of the genomic potential of producers via "genome mining". Challenges that exist beyond compound discovery are outlined in the last section.

KEYWORDS:

Actinobacteria; Antibiotics; Biodiversity; Genomic potential; Myxobacteria

PMID:
24119567
DOI:
10.1016/j.ijmm.2013.09.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center